Pfizer has reported 82% operating revenue growth to $ 25.7 billion in the first quarter (Q1) of 2022 compared to $ 14.5 billion in the quarter a year ago.
Operationally, revenues increased by 2% excluding contributions from Comirnaty and Paxlovid.
Comirnaty is a vaccine against Covid-19, while Paxlovid is an oral antiviral product against Covid-19.
For the quarter, operating growth was mainly due to global sales of Comirnaty, Paxlovid, Eliquis, Vyndaqel / Vyndamax and sales of the Prevnar family in the United States.
The growth was partially offset by reduced revenues from Chantix and Xeljanz worldwide and Ibrance in the United States.
In the first quarter of 2022, reported diluted earnings per share (EPS) were $ 1.37 compared to $ 0.86 in the first quarter of 2021, reflecting a 59% jump.
In addition, the first quarter of 2022 saw a 72% increase in adjusted diluted earnings per share to $ 1.62 compared to $ 0.95 in the second quarter of 2021.
Pfizer Chairman and CEO Dr. Albert Burla said: “I am very proud of our performance this quarter, both financially and in our efforts to be a force for good in the world.
“We continue to deliver Comirnaty to the world, which remains a critical tool to help patients and societies avoid the worst of the Covid-19 pandemic, and we are on track to deliver on at least two billion doses to low- and mid-range countries.” income in 2021 and 2022, including at least one billion doses this year.
The company also confirmed financial guidelines for the whole of 2022 for revenues ranging between $ 98 billion and $ 102 billion.
Pfizer also confirmed the 2022 revenue guidelines for Comirnaty and Paxlovid of nearly $ 32 billion and $ 22 billion, respectively.
The full financial guidelines for 2022 for adjusted diluted EPS have been updated to $ 6.25- $ 6.45 from the previous range of $ 6.35- $ 6.55.
In February this year, the company reported revenue of $ 81.3 billion for the full year 2021 compared to $ 41.7 billion for the full year 2020, which shows 92% operating growth.